{
  "id": "5c6b7bee7c78d6947100002a",
  "type": "yesno",
  "question": "Is dupilumab effective for treatment of asthma?",
  "ideal_answer": "Yes, dupilumab is effective for treatment of asthma. It works by simultaneous targeting of both IL-4 and IL-13 by blocking IL-4 receptor \u03b1.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27334730",
    "http://www.ncbi.nlm.nih.gov/pubmed/29782224",
    "http://www.ncbi.nlm.nih.gov/pubmed/29782217",
    "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
    "http://www.ncbi.nlm.nih.gov/pubmed/28979129",
    "http://www.ncbi.nlm.nih.gov/pubmed/28547386",
    "http://www.ncbi.nlm.nih.gov/pubmed/28990423",
    "http://www.ncbi.nlm.nih.gov/pubmed/29036019",
    "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
    "http://www.ncbi.nlm.nih.gov/pubmed/29939132",
    "http://www.ncbi.nlm.nih.gov/pubmed/25214796",
    "http://www.ncbi.nlm.nih.gov/pubmed/23688323",
    "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
    "http://www.ncbi.nlm.nih.gov/pubmed/29355679",
    "http://www.ncbi.nlm.nih.gov/pubmed/28971769",
    "http://www.ncbi.nlm.nih.gov/pubmed/30167841",
    "http://www.ncbi.nlm.nih.gov/pubmed/28478972"
  ],
  "snippets": [
    {
      "text": "The appropriate use of these biologics, and of those in development (e.g., benralizumab and dupilumab), should be aided by further understanding of asthma phenotypes and endotypes, utilizing appropriate biomarkers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Simultaneous targeting of both IL-4 and IL-13 by blocking IL-4 receptor \u03b1 using dupilumab has yielded more consistent results in reducing asthma exacerbations and improving lung function, especially in patients with increased blood eosinophils.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036019",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a pivotal, phase 2b study (NCT01854047), dupilumab reduced severe exacerbations, improved lung function and quality of life, and was generally well tolerated in patients with uncontrolled persistent asthma despite using medium-to-high-dose inhaled corticosteroids plus long-acting \u03b22-agonists.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Dupilumab 300\u00a0mg q2w significantly improved AR-associated nasal symptoms in patients with uncontrolled persistent asthma and comorbid PAR.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Small molecules (e.g. ligustrazine and SP600125) and large molecule antibodies (e.g. lebrikizumab, benralizumab, dupilumab) are being considered as novel agents for the pharmacotherapy of asthma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28971769",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29782217",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: In this trial, patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29782217",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab for the treatment of asthma.Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "If confirmed, efficacy of dupilumab in both eosinophilic and non-eosinophilic severe asthma phenotype might represent an advantage over approved biologics for asthma, including omalizumab, mepolizumab, and reslizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this review, we focused on IL-4 and IL-13, as these interleukins are considered to play a key role in the pathophysiology of asthma, and on dupilumab, an anti-IL-4 receptor human mAb, as a forthcoming treatment for uncontrolled severe asthma in the near future.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28979129",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Supported by a strategic mechanism of action, as well as by convincing preliminary clinical results, dupilumab currently appears to be a very promising biological drug for the treatment of severe uncontrolled asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28990423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All drugs decreased asthma exacerbations but the results were only significant for reslizumab and dupilumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30167841",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anti-IL-4 and IL-13 agents (dupilumab, lebrikizumab, and tralokinumab) which block different Th-2 inflammatory pathways and agents targeting the Th-17 inflammatory pathway in severe refractory asthma are under development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27334730",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab for the treatment of asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In addition, dupilumab is currently under phase\u00a0III development across the world for the treatment of asthma and nasal polyposis as well as for atopic dermatitis in paediatric patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28547386",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nDupilumab (an anti-interleukin-4-receptor-\u03b1 monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28478972",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab: a novel treatment for asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25214796",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Dupilumab for the treatment of asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28990423",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The efficacy and safety profile of dupilumab in the treatment of allergic diseases has been tested for more than 10 years in a variety of large clinical trials in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29939132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: Pathophysiological role of IL-4 and IL-13 in asthma; mechanism of action of dupilumab; pharmacology of IL-4 receptor; phase I and phase II studies with dupilumab; regulatory affairs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Patients with severe asthma who are not sufficiently controlled with standard-of-care represent the target asthma population for dupilumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS In patients with glucocorticoid-dependent severe asthma, dupilumab treatment reduced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the FEV1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29782224",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with fewer asthma exacerbations when LABAs and inhaled glucocorticoids were withdrawn, with improved lung function and reduced levels of Th2-associated inflammatory markers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23688323",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Patients with severe asthma who are not sufficiently controlled with standard-of-care represent the target asthma population for dupilumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Supported by a strategic mechanism of action, as well as by convincing preliminary clinical results, dupilumab currently appears to be a very promising biological drug for the treatment of severe uncontrolled asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28990423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A recent trial showed that in patients with difficult-to-control asthma, dupilumab can markedly decrease asthma exacerbations and improve respiratory symptoms and lung function; these effects were paralleled by significant reductions in T-helper 2-associated inflammatory biomarkers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25214796",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}